Endometrial Cancer

Casadio, Paolo; Magnarelli, Giulia; Alletto, Andrea; Guasina, Francesca; Morra, C; Talamo, Maria; Rosa, Michele La; Su, Hsuan; Frisoni, Jessica; Seracchioli, Renato

doi:10.1007/978-3-030-29466-3_15

Cited by 2 publications

(1 citation statement)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptomatic women in the UK are triaged with a transvaginal ultrasound scan (TVS), a highly sensitive test that is limited by its poor specificity. Depending on the endometrial thickness, around 50% undergo further tests, specifically endometrial biopsy with or without hysteroscopy [ 5 , 11 ]. These procedures are expensive and invasive, and can be painful, especially in nulliparous women, and carry a small risk of life-threatening uterine perforation and other serious complications [ 5 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Endometrial Cancer Stem Cells Related Signaling Pathways

Farzaneh

Pour

Keivan

et al. 2023

CCTR

View full text Add to dashboard Cite

Endometrial cancer is gynecologic cancer that occurs in the uterus. Endometrial cancer stem cells (ECSC) are a small population of cancer cells that represent a crucial role in the metastasis of endometrial cancer cells to other organs in the body. ECSC can proliferate and give rise to mature cancer cells, which are found to participate in the aggressiveness of metastatic lesions. Therefore, targeting ECSC can be a valuable strategy for drug development against the metastasis of endometrial cancer. Previous studies have demonstrated that several signaling pathways, including Wnt, mTOR, EGFR, NOTCH, STAT3, VEGF, and SHH show modest effects and regulate the growth, epithelial-to-mesenchymal transition (EMT), and tumorigenesis of ECSC. Non-coding RNAs (ncRNAs) also play an important role in ECSC self-renewal, progression, and drug resistance. Hence, targeting these pathways might be a novel therapeutic approach for endometrial cancer diagnosis and therapy. This mini-review aims to characterize the main signaling pathways involved in the stimulation of ECSCs proliferation and tumorigenesis.

show abstract

Endometrial Cancer

Cited by 2 publications

References 84 publications

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

Endometrial Cancer Stem Cells Related Signaling Pathways

Contact Info

Product

Resources

About